36
Participants
Start Date
December 6, 2022
Primary Completion Date
December 6, 2023
Study Completion Date
September 26, 2024
Ibrutinib
Ibrutinib capsules will be administered orally.
Lenalidomide
Lenalidomide capsules will be administered orally.
Rituximab
Rituximab will be administered IV.
Bortezomib
Bortezomib will be administered either intravenously or subcutaneously.
National Taiwan University Hospital, Taipei
Chi Mei Medical Center Liu Ying, Tainan City
King Chulalongkorn Memorial Hospital, Bangkok
Phramongkutklao Hospital and Medical College, Bangkok
Ramathibodi Hospital, Bangkok
Siriraj Hospital, Bangkok
Attikon University General Hospital of Attica, Athens
Hosp Reina Sofia, Córdoba
Trakya University Medical Faculty, Edirne
Hosp. Univ. Infanta Leonor, Madrid
Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcón
Clinica Univ. de Navarra, Pamplona
Medipol Mega University Hospital, Istanbul
Istanbul University, Istanbul
Ege Universitesi Tip Fakultesi, Izmir
Hosp Clinico Univ de Salamanca, Salamanca
Srinagarind Hospital, Khon Kaen
University Hospital of Ioannina, Ioannina
Subang Jaya Medical Centre, Subang Jaya
Maharaj Nakorn Chiang Mai hospital Faculty of Medicine, Chiang Mai
Sakarya Egitim Ve Arastırma Hastanesi Korucuk Kampus, Sakarya
Ondokuz Mayis University, Atakum
G.Papanikolaou, Thessaloniki
University Malaya Medical Centre, Kuala Lumpur
Hospital Ampang, Ampang
Samodzielny Publiczny Szpital Kliniczny Nr 1 PUM im prof Tadeusza Sokolowskiego w Szczecinie, Szczecin
Hospital Sultanah Aminah, Johor Bharu
Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung City
Hospital Queen Elizabeth, Kota Kinabalu
Sunderby Sjukhus, Luleå
Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur
HCG cancer center, Jaipur
Synergy Superspeciality Hospital, Rajkot
China Medical University Hospital, Taichung
Deenanath Mangeshkar Hospital and Research Centre, Pune
American Oncology Institute Cancer Treatment Hospital Hyderabad, Hyderabad
Healthcare Global (HCG) Hospital, Bangalore
AMRI Hospital, Mukundapur, Mukundapur
Tata Medical Center, Kolkata
Ovidius Clinical Hospital OCH, Ovidiu
Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte
Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia, Brasília
Ynova Pesquisa Clinica, Florianópolis
Liga Norte Riograndense Contra O Cancer, Natal
Complexo Hospitalar de Niteroi, Niterói
Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre
Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP, Ribeirão Preto
Oncoclinicas Rio de Janeiro S A, Rio de Janeiro
Instituto de Ensino e Pesquisa Sao Lucas - IEP HEMOMED, São Paulo
Instituto D Or de Pesquisa e Ensino IDOR, São Paulo
Casa de Saude Santa Marcelina - Hospital Santa Marcelina, São Paulo
Fakultni Nemocnice Ostrava, Ostrava
Fakultni nemocnice Kralovske Vinohrady, Prague
General University Hospital in Prague, Prague
Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza, Brzozów
Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Kielce
Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie, Lublin
Szpital Specjalistyczny im Jedrzeja Sniadeckiego w Nowym Saczu, Nowy Sącz
SPZOZ Ministerstwa Spraw Wewnetrznych z Warminsko Mazurskim Centrum Onkologii w Olsztynie, Olsztyn
Centrum Medyczne Pratia Poznan, Skorzewo
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw
Specjalistyczny Szpital im dra Alfreda Sokolowskiego w Walbrzychu, Wałbrzych
Auxilio Mutuo Cancer Center, San Juan
Spitalul Clinic Coltea, Bucharest
Falu Lasarett Medicinkliniken Falun, Falun
Ankara Bilkent Sehir Hastanesi, Ankara Sehir Hastanesi
Collaborators (1)
Pharmacyclics LLC.
INDUSTRY
Janssen Research & Development, LLC
INDUSTRY